INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Malignancies|Metastatic Cancer
Interventions: DRUG: INCAGN01876|DRUG: Epacadostat|DRUG: Pembrolizumab
Sponsor: Incyte Biosciences International Sàrl